Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 1;37(7):1159-1160.
doi: 10.1097/QAD.0000000000003539.

Point-of-care urine tenofovir testing: making a good thing better

Mauro Zaccarelli  1 , Bienvenu Niyongabo  2 , Brian Conway  3
Affiliations
Editorial

Point-of-care urine tenofovir testing: making a good thing better

Mauro Zaccarelli et al. AIDS. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. South African National Department of Health. 2019 ART clinical guidelines for the management of HIV in adults, pregnancy, adolescents, children, infants, and neonates. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955519/ .
    1. Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 noninferiority trial in Cameroon . Lancet HIV 2020; 7:e677–e687.
    1. McCluskey SM, Govender K, Adamson J, Ghandi M, Spinelli MA, Moosa MY, et al. Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure . AIDS 2023; 37:1109–1113.
    1. Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, et al. Dolutegravir for first-line antiretroviral therapy in low income and middle-income countries: uncertainties and opportunities for implementation and research . Lancet HIV 2018; 5:e400–e404.
    1. Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection . AIDS 2022; 36:39–48.